Park Christopher S, Nadeem Amin
Department of Internal Medicine, Chicago Medical School at Rosalind Franklin University of Medicine and Science, North Chicago, USA.
Section of Critical Care, Captain James Lovell FHCC (Federal Health Care Center) and Rosalind University of Medicine and Science, North Chicago, USA.
Cureus. 2023 Dec 19;15(12):e50787. doi: 10.7759/cureus.50787. eCollection 2023 Dec.
Regadenoson (brand name Lexiscan) is a specific adenosine receptor agonist commonly used in pharmacologic stress testing due to its coronary vasodilatory effects. Despite it being generally well-tolerated, the American Society of Nuclear Cardiology established absolute and relative contraindications to the use of regadenoson in patients with certain co-morbidities such as uncontrolled hyper/hypotension, sinus node disease, and second-degree heart blocks. While cases of advanced heart block after the administration of regadenoson have been reported, they remain incidental. We report the case of an 84-year-old male sustaining second-degree type II heart block, followed by pulseless electrical activity and asystole after the administration of regadenoson.
雷加昔布(商品名Lexiscan)是一种特定的腺苷受体激动剂,因其冠状动脉舒张作用常用于药物负荷试验。尽管它通常耐受性良好,但美国核心脏病学会确定了在某些合并症患者(如未控制的高血压/低血压、窦房结疾病和二度心脏传导阻滞)中使用雷加昔布的绝对和相对禁忌症。虽然已有使用雷加昔布后发生高级别心脏传导阻滞的病例报告,但这些仍属偶发情况。我们报告了一例84岁男性在使用雷加昔布后发生二度II型心脏传导阻滞,随后出现无脉性电活动和心脏停搏的病例。